Overview

Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation

Status:
Not yet recruiting

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

To investigate limited course of treatment of Zebutinib combined with immunochemotherapy for patients with newly treated chronic lymphocytic leukemia without 17p-/TP53 mutation

Phase:

Phase 3

Details

Lead Sponsor:

Nanfang Hospital of Southern Medical University